Femke De Snoo

630 citations

45 papers · 444 indexed · h-index 11

Cancer Research top 10%
- Breast Cancer Treatment Studies 34
- Cancer Genomics and Diagnostics 17
Oncology
- HER2/EGFR in Cancer Research 9
- Cancer Cells and Metastasis 3
Genetics
- BRCA gene mutations in cancer 2
Neurology
Molecular Biology
- Gene expression and cancer classification 3
Radiology, Nuclear Medicine and Imaging
- Radiomics and Machine Learning in Medical Imaging 10
Pulmonary and Respiratory Medicine
- Advanced Breast Cancer Therapies 7

Co-authors: Lisette Stork‐Sloots Annuska M. Glas Stefan Glück Justine Peeters Paul Roepman George Somlo René Bernards Sun Tian
Cited by: Cancer Research Oncology Genetics
Journals: Journal of Clinical Oncology (16 papers)Journal of Neuroscience (1 paper)SHILAP Revista de lepidopterología (1 paper)
Partner nations: United States Netherlands Italy

In The Last Decade

Femke De Snoo

41 papers receiving 420 citations

Peers

Countries citing papers authored by Femke De Snoo

Since Specialization

Citations

This map shows the geographic impact of Femke De Snoo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Femke De Snoo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Femke De Snoo more than expected).

Fields of papers citing papers by Femke De Snoo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Femke De Snoo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Femke De Snoo. The network helps show where Femke De Snoo may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Femke De Snoo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Femke De Snoo Line = papers co-authored together Femke De Snoo links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Abstract P5-17-08: A phase Ib/II study of leronlimab combined with carboplatin in patients with CCR5+ metastatic triple-negative breast cancer (mTNBC) Cancer Research ·Massimo Cristofanilli,Namita Chittoria,Sima Ehsani,Hallgeir Rui,Marek Doležal,Lisette Stork‐Sloots,Femke De Snoo,Christopher Recknor,Vandana G. Abramson	2022	6
2	Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial SHILAP Revista de lepidopterología ·Noa Biran,Binod Dhakal,Suzanne Lentzsch,David S. Siegel,Saad Z. Usmani,Adriana Rossi,Cara A. Rosenbaum,Divaya Bhutani,David H. Vesole,Cesar Rodriguez,Ajay K. Nooka,Frits van Rhee,Lisette Stork‐Sloots,Femke De Snoo,Pritish K. Bhattacharyya,Durga Prasad Dash,Sena Zümrütçü,Martin H. van Vliet,Parameswaran Hari,Rubén Niesvizky	2021	9
3	Prospective study to measure the impact of MMprofiler on treatment intention in newly diagnosed multiple myeloma patients (PROMMIS). Journal of Clinical Oncology ·Parameswaran Hari,Suzanne Lentzsch,David S. Siegel,Saad Z. Usmani,Binod Dhakal,Adriana Rossi,Cara A. Rosenbaum,Siyang Leng,Divaya Bhutani,Noa Biran,David H. Vesole,Manisha Bhutani,Lisette Stork‐Sloots,Femke De Snoo,Belinda Dumee,M. van Vliet,Rubén Niesvizky	2019	2
4	Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Annals of Surgical Oncology ·Peter D. Beitsch,Pat W. Whitworth,Paul L. Baron,Michael Rotkis,Angela Mislowsky,Paul Richards,Mary K. Murray,James Pellicane,Carrie L. Dul,Charles H. Nash,Lisette Stork‐Sloots,Femke De Snoo,Sarah Untch,Laura A. Lee	2017	28
5	Not all small node negative (pT1abN0) breast cancers are similar: Outcome results from an EORTC 10041/BIG 3-04 (MINDACT) trial substudy Annals of Oncology ·K. Tryfonidis,Coralie Poncet,Leen Slaets,Giuseppe Viale,Femke De Snoo,K.C. Aalders,Laura van ‘t Veer,Emiel J. Rutgers,Martine Piccart,Jan Bogaerts,Fátima Cardoso	2017	2
6	An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·Jelle Wesseling,Corrado Tinterri,Anna Sapino,Fabrizio Zanconati,Martijn Lutke-Holzik,Bichlien Nguyen,Kenneth Deck,Patrizia Querzoli,Tiziana Perin,C Giardina,Gerhard Seitz,J M Guinebretière,Julie Barone,Laura Dekker,Femke De Snoo,Lisette Stork‐Sloots,Paul Roepman,Toru Watanabe,P. Cusumano	2016	10
7	Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups Breast Cancer Research and Treatment ·Katharine Yao,Robert Goldschmidt,Mary Turk,Jelle Wesseling,Lisette Stork‐Sloots,Femke De Snoo,Massimo Cristofanilli	2015	17
8	Application of a 70-Gene Expression Profile to Japanese Breast Cancer Patients Breast Care ·Hideo Shimizu,Yoshiya Horimoto,Atsushi Arakawa,Hiroshi Sonoue,Mami Kurata,Taijiro Kosaka,Katsuya Nakai,Takanori Himuro,Emi Tokuda,Yuka Takahashi,Fumi Taira,Mayuko Ito,Ikuko Abe,Koji Senuma,Lisette Stork‐Sloots,Femke De Snoo,Mitsue Saito	2015	5
9	Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy Medical Oncology ·Soley Bayraktar,Melanie Royce,Lisette Stork‐Sloots,Femke De Snoo,Stefan Glück	2014	14
10	European inter-institutional impact study of MammaPrint The Breast ·P. Cusumano,Daniele Generali,Eva Ciruelos,Luís Manso,Ismael Ghanem,Éric Lifrange,Guy Jérusalem,Joost M. Klaase,Femke De Snoo,Lisette Stork‐Sloots,L. Dekker-Vroling,M. Lutke Holzik	2014	18
11	Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy Breast Cancer Research and Treatment ·Stefan Glück,Femke De Snoo,Justine Peeters,Lisette Stork‐Sloots,George Somlo	2013	76
12	Abstract P6-06-02: Direct comparison of risk classification between MammaPrint®, Oncotype DX® and MammoStrat® assays in patients with early stage breast cancer Cancer Research ·SC Shivers,Linda C. Clark,N. Esposito,Natasha Howard,Jeff King,Géza Ács,D Ellis,V Vrcelj,Antonela Zanchi,Lisette Stork‐Sloots,Femke De Snoo,FL Baehner,SM Butler,F Jamshadian,AP Sing,PW Blumencranz,CE Cox	2013	8
13	Molecular and clinical characterization of patients with a ring chromosome 11 European Journal of Medical Genetics ·Kerstin Hansson,Antoinet C.J. Gijsbers,Wilma Oostdijk,Jan J.B. Rehbock,Femke De Snoo,Claudia Ruivenkamp,Sarina G. Kant	2012	16
14	Comparison of molecular (BluePrint and MammaPrint) and pathological subtypes for breast cancer among the first 800 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial. Journal of Clinical Oncology ·Giuseppe Viale,Leen Slaets,Femke De Snoo,Laura van ‘t Veer,Emiel J. Rutgers,Jan Bogaerts,Lisette Stork‐Sloots,Kristel Engelen,Leila Russo,Patrizia Dell’Orto,Fátima Cardoso,Martine Piccart	2012	1
15	Genomic analysis: Toward a new approach in breast cancer management Critical Reviews in Oncology/Hematology ·Sebastiano Cavallaro,Sabrina Paratore,Femke De Snoo,Edvige Salomone,Loredana Villari,Calogero Buscarino,Francesco Ferraù,Giuseppe Luigi Banna,M Furci,Angela Strazzanti,Rosario Cunsolo,Salvatore Pezzino,Santi Gangi,Francesco Basile	2011	15
16	Gene signatures as predictors of response to neoadjuvant chemotherapy (NCT) with docetaxel, doxorubicin, cyclophosphamide (TAC), or AC and nab-paclitaxel (nab-P) and carboplatin ± trastuzumab in patients (pts) with stage II-III and inflammatory breast cancer (IBC). Journal of Clinical Oncology ·George Somlo,Paul Frankel,Lalitkumar K. Vora,Sean K. Lau,Thehang Luu,Laura Kruper,JH Yim,Yi‐Ting Yen,Femke De Snoo,Richard A. Bender	2010	8
17	Biological Functions of the Genes in the Mammaprint Breast Cancer Profile Reflect the Hallmarks of Cancer Biomarker Insights ·Sun Tian,Paul Roepman,Laura J. van’t Veer,René Bernards,Femke De Snoo,Annuska M. Glas	2010	95
18	0074 Early prognosis prediction: MammaPrint on core-needle biopsies The Breast ·Femke De Snoo,Annuska M. Glas,Arno Floore,Juan Mayordomo‐Colunga,A. Modollel,Christian Rolfo,L. van 't Veer,Emiel J. Rutgers,Sjoerd Rodenhuis,R Joseph Bender	2009	0
19	Gene expression profiling: Decoding breast cancer Surgical Oncology ·Femke De Snoo,Richard A. Bender,Annuska M. Glas,Emiel J. Rutgers	2009	22
20	Selective Degeneration of Purkinje Cells with Lewy Body-Like Inclusions in Aged NFHLACZ Transgenic Mice Journal of Neuroscience ·Pang‐Hsien Tu,Kathryn A. Robinson,Femke De Snoo,Joël Eyer,Alan C. Peterson,Virginia M.‐Y. Lee,John Q. Trojanowski	1997	53

About Femke De Snoo

Femke De Snoo is a scholar working on Cancer Research, Oncology and Radiology, Nuclear Medicine and Imaging, having authored 45 papers that have together received 444 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (34 papers), Cancer Genomics and Diagnostics (17 papers), Radiomics and Machine Learning in Medical Imaging (10 papers), HER2/EGFR in Cancer Research (9 papers), Advanced Breast Cancer Therapies (7 papers), Cancer Cells and Metastasis (3 papers), Gene expression and cancer classification (3 papers) and BRCA gene mutations in cancer (2 papers). The work is most often cited by research in Cancer Research (257 citations), Oncology (210 citations) and Genetics (77 citations). Femke De Snoo has collaborated with scholars based in United States, Netherlands and Italy. Frequent co-authors include Lisette Stork‐Sloots, Annuska M. Glas, Stefan Glück, Justine Peeters, Paul Roepman, George Somlo, René Bernards, Sun Tian, Laura J. van’t Veer and John Q. Trojanowski. Their work appears in journals such as Journal of Clinical Oncology, Journal of Neuroscience and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact